Wiesmann is an accomplished physician, medical scientist, and program manager with experience in cell biology, systems biology, medical device development and extensive experience leading and conducting basic scientific and medical research. - Rob Ayling is CEO. We were able to fulfill the immediate orders from wholesalers and enabled dispensing of prescriptions from physicians interested in offering this innovative treatment option with their patients. He holds 59 awarded or pending patents from his work in biosensors, automated diagnostic devices, advanced tissue engineering, wound care, and infection control. Dr. Wiesmann has been published in more than 75 peer-reviewed medical journals.Dr. Wiesmann has received many honors for his development work in government, including the US Army Meritorious Service Medal, the US Army R & D Achievement Award, and the Army Commendation Medal. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a bachelor’s degree from St. Mary’s Hospital, University of London and a medical degree from St. Bartholomew’s Hospital, University of London.Andrew Miller is the President and CEO of Stimson Lumber Company in Portland, Oregon. Nicholas Bishop - Cowen and Company, LLC, Research Division Having gained approval for BYDUREON in the United States in late January, we immediately began executing our comprehensive launch plan.
The text of the letter from Daniel M. Bradbury, President and Chief Executive Officer, and James N. Wilson, Lead Independent Director, is below: Former President and Chief Executive Officer, Amylin Pharmaceuticals Ms. Graham is the former President and Chief Executive Officer of Two Trees Consulting, Inc., a healthcare and executive leadership consulting firm, where she served from November 2007 to December 2016. Let me introduce the other members of the Amylin management team here today: Daniel Bradbury, President and Chief Executive Officer; Mark Foletta, Senior Vice President of Finance and Chief Financial Officer; and Vince Mihalik, Senior Vice President, Sales and Marketing and Chief Commercial Officer. Amylin Pharmaceuticals is a biopharmaceutical firm located in San Diego, California, with over 1,000 employees in the US. We now have a total of 650 reps hired, trained and in the field, supporting Exenatide, and an additional 65 reps trained and in the field detailing SYMLIN and BYETTA. He served as the Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command Post, at Ft. Detrick, where he led the design and development teams that produced novel technologies for improved battlefield survival until he retired from the Army as a colonel in 1997. During her tenure at Althea Technologies, Dr. Marquet had full P&L responsibility and built an organization with R&D and international commercial capabilities. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. Rob co-founded Finistere Partners originally as an agbio focused consulting business which now manages a small strategic investment fund. Dr. Baker was a professor of Chemistry at Harvey Mudd College from 1991-2014 with a research focus on polymer nanostructures and self-assembly at liquid and solid interfaces. Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas.
Dr. Eng discovered exendin-4 in the venom of a 1992 - 1998: Invention of Pramlintide & Partnership with Johnson & Johnson1998 - 2005: New Leadership, Struggle to Launch Pramlintide (Symlin), Development of Byetta (Exenatide)2011 - 2012: End of collaboration with Eli Lilly and Acquisition1992 - 1998: Invention of Pramlintide & Partnership with Johnson & Johnson1998 - 2005: New Leadership, Struggle to Launch Pramlintide (Symlin), Development of Byetta (Exenatide)2011 - 2012: End of collaboration with Eli Lilly and Acquisition With the hard work of the Amylin organization and all our suppliers, BYDUREON was available to patients within 12 business days of approval.
His innovations, which include the LSTAT Transportable Life Support System, the Advanced Surgical Suite for Trauma Casualties (ASSTC), the SAVe ventilators, and the HemCon hemostatic bandages, have transformed medicine both on the battlefield and in civilian trauma centers.
Mark G. Foletta - Chief Financial Officer and Senior Vice President of Finance He also serves as the Managing Member of BioBrit, a life sciences consulting and investment firm. Terence C. Flynn - Goldman Sachs Group Inc., Research Division
This morning, our comments will build on the press release issued earlier today. With BYDUREON, we have set a new bar for the treatment options that we believe will start further innovation and advancements that will continue to revolutionize the development of future therapies for people with diabetes. In 1987, Amylin Pharmaceuticals was co-founded by Howard E. Greene Jr., former CEO of San Diego biotech pioneer Hybridtech, to develop a treatment for diabetes from a synthetic analog of amylin.
Previously, Ms. Clague served as chief financial officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. With prescriptions, the GLP-1 receptor agonists having grown by nearly 60% since February 2010 and the class now approaching 2 billion in global sales, we believe that awareness of the benefits of GLP-1 therapy is at an all-time high. He also serves as the Managing Member of BioBrit, a life sciences consulting and investment firm. - Carey Ng is a board member. He has been Principal Investigator on 5 FDA sponsored clinical trials and received over $30 million in grants to research novel techniques for the repair and replacement of tissues.Paul Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences, which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Incorporated, Research Division This therapy is now approved in 35 markets around the world and has launched in 15 to date. He serves on the board of directors of Intercept Pharmaceuticals and a number of private companies and philanthropic organizations.Dr.